Efficacy of Prostate-Specific Antigen Screening: Use of Regression Discontinuity in the PLCO Cancer Screening Trial

JAMA Oncol. 2015 Oct;1(7):984-6. doi: 10.1001/jamaoncol.2015.2993.

Authors

Jonathan Shoag¹, Joshua Halpern¹, Brian Eisner², Richard Lee¹, Sameer Mittal¹, Christopher E Barbieri¹, Daniel Shoag³

Affiliations

¹ Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York.
² Department of Urology, Massachusetts General Hospital, Boston.
³ Department of Public Policy, Harvard Kennedy School, Cambridge, Massachusetts.

PMID: 26291583
DOI: 10.1001/jamaoncol.2015.2993

No abstract available

Publication types

Letter
Randomized Controlled Trial

MeSH terms

Biopsy
Data Interpretation, Statistical
Digital Rectal Examination
Early Detection of Cancer / methods*
Humans
Kallikreins / blood*
Male
Predictive Value of Tests
Prognosis
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / blood*
Prostatic Neoplasms / mortality
Prostatic Neoplasms / pathology
Regression Analysis
Time Factors

Substances

KLK3 protein, human
Kallikreins
Prostate-Specific Antigen